Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 18, 2006New England Journal of Medicine

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJoel E. GallantGilead Sciences (United States)EDEdwin DeJesusOrlando Immunology CenterJAJosé Ramón ArribasHospital Universitario La Paz

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gallant et al. (2006) studied this question.

synapsesocial.com/papers/6a1a56be353de69e89b875adhttps://doi.org/10.1056/nejmoa051871
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Antiretroviral Treatment Patterns and Incident HIV-Associated Morphologic and Lipid Abnormalities in a Population-Based Cohort2002 · 97 citations
  2. 2Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral‐Naive HIV‐Infected Adults2004 · 226 citations
  3. 3Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir2004 · 297 citations
  4. 4Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel2003 · 516 citations